Single CAR-Dual target: Intracranial Delivery of Anti-PD-L1 CAR T Cells Effectively Eradicates Glioma and Immunosuppressive Cells in the Tumor Microenvironment. DOI Creative Commons
María José Ulloa-Navas, Yan Luo,

Jesus Emiliano Sanchez-Garavito

и другие.

bioRxiv (Cold Spring Harbor Laboratory), Год журнала: 2024, Номер unknown

Опубликована: Ноя. 24, 2024

With the goal to overcome limited treatment options and poor prognosis of glioblastoma (GBM), we have developed a PD-L1-targeting CAR T cell therapy, MC9999. In vitro experiments with MC9999 cells derived from GBM patients exhibited potent, antigen-specific cytotoxicity against autologous tumor immunosuppressive within microenvironment (TME). an orthotopic model using patient-derived brain tumor-initiating cells, intracranial delivery eradicated established tumors improved survival. Single-cell RNA sequencing indicated that activate interferon pathways, leading apoptosis. Multi-immunohistochemistry confirmed localized PD-L1 expression on TME-residing macrophages, but not in neurons or glia patient tissue. The local may be safe, effective approach for simultaneously targeting PD-L1-positive its TME strategy immune evasion enhance therapeutic potency therapy GBM.

Язык: Английский

A new sort of cells for CAR T-cell therapies— Isolating CD14–CD127+ T cells for CAR T-cell manufacture DOI
Yan Luo,

Yaqing Qie,

Martha E. Gadd

и другие.

Cytotherapy, Год журнала: 2025, Номер unknown

Опубликована: Апрель 1, 2025

Язык: Английский

Процитировано

0
Tumor-Associated Macrophages: Polarization, Immunoregulation, and Immunotherapy DOI Creative Commons
Abdullah F. U. H. Saeed

Cells, Год журнала: 2025, Номер 14(10), С. 741 - 741

Опубликована: Май 19, 2025

Tumor-associated macrophages’ (TAMs) origin, polarization, and dynamic interaction in the tumor microenvironment (TME) influence cancer development. They are essential for homeostasis, monitoring, immune protection. Cells from bone marrow or embryonic progenitors dynamically polarize into pro- anti-tumor M2 M1 phenotypes based on cytokines metabolic signals. Recent advances TAM heterogeneity, characterization, immunological responses, therapy described here. The manuscript details functions their role resistance to PD-1/PD-L1 blockade. Similarly, TAM-targeted approaches, such as CSF-1R inhibition PI3Kγ-driven reprogramming, discussed address immunity suppression. Furthermore, innovative biomarkers combination may enhance TAM-centric therapies. It also stresses relevance of this distinct cell human health disease, which could impact future research

Язык: Английский

Процитировано

0
Single CAR-Dual target: Intracranial Delivery of Anti-PD-L1 CAR T Cells Effectively Eradicates Glioma and Immunosuppressive Cells in the Tumor Microenvironment. DOI Creative Commons
María José Ulloa-Navas, Yan Luo,

Jesus Emiliano Sanchez-Garavito

и другие.

bioRxiv (Cold Spring Harbor Laboratory), Год журнала: 2024, Номер unknown

Опубликована: Ноя. 24, 2024

With the goal to overcome limited treatment options and poor prognosis of glioblastoma (GBM), we have developed a PD-L1-targeting CAR T cell therapy, MC9999. In vitro experiments with MC9999 cells derived from GBM patients exhibited potent, antigen-specific cytotoxicity against autologous tumor immunosuppressive within microenvironment (TME). an orthotopic model using patient-derived brain tumor-initiating cells, intracranial delivery eradicated established tumors improved survival. Single-cell RNA sequencing indicated that activate interferon pathways, leading apoptosis. Multi-immunohistochemistry confirmed localized PD-L1 expression on TME-residing macrophages, but not in neurons or glia patient tissue. The local may be safe, effective approach for simultaneously targeting PD-L1-positive its TME strategy immune evasion enhance therapeutic potency therapy GBM.

Язык: Английский

Процитировано

0